GAITHERSBURG, Md. — January 8, 2026 — Leads & Copy — Emergent BioSolutions (NYSE: EBS) announced today that it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax® (Anthrax Vaccine Adsorbed) in 2026.
This order falls under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract (W911SR24D0001), led by the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), previously the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency.
Deliveries under this order will take place in 2026. The order includes a one-year base period, with two additional option periods for 2027 and 2028.
BioThrax® vaccine is indicated for active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age. It is approved for pre-exposure prophylaxis of disease in persons at high risk of exposure, and for post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered with recommended antibacterial drugs. The efficacy of BioThrax® for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax.
Emergent BioSolutions’ senior vice president, head of products business, global government and public affairs, Paul Williams, stated the company is proud to help protect those who protect the nation, including service members, and is pleased to continue its partnership with the U.S. Department of War to supply BioThrax® to prepare military personnel at high risk of anthrax exposure.
Important Safety Information for BioThrax® includes contraindications for individuals with severe allergic reaction after a previous dose of BioThrax® or a component of the vaccine. The stopper of the vial contains natural rubber latex, which may cause allergic reactions in latex-sensitive individuals. Use in pregnancy should be avoided unless the potential benefit outweighs the potential risk to the fetus. The most common local adverse reactions observed in clinical studies were tenderness, pain, erythema, edema, and arm motion limitation. The most common systemic adverse reactions were muscle aches, fatigue, and headache.
At Emergent, the mission is to protect and save lives. For over 25 years, the company has been preparing those entrusted with protecting public health, delivering protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
Source: Emergent BioSolutions
